- Approval Id
- 6a3fe55f4dbfb247
- Drug Name
- RHOPRESSA OPHTHALMIC SOLUTION, 0.02% w/v
- Product Name
- RHOPRESSA OPHTHALMIC SOLUTION, 0.02% w/v
- Approval Number
- SIN16816P
- Approval Date
- 2023-07-04
- Registrant
- SANTEN PHARMACEUTICAL ASIA PTE. LTD.
- Licence Holder
- SANTEN PHARMACEUTICAL ASIA PTE. LTD.
- Drug Type
- Therapeutic
- Forensic Classification
- Prescription Only
- Dosage Form
- SOLUTION, STERILE
- Dosage
- <p><strong>2. DOSAGE AND ADMINISTRATION</strong><br>
The recommended dosage is one drop in the affected eye(s) once daily in the evening.</p>
<p>If one dose is missed, treatment should continue with the next dose in the evening. Twice a day dosing is not well tolerated and is not recommended. If RHOPRESSA is to be used concomitantly with other topical ophthalmic drug products to lower IOP, administer each drug product at least 5 minutes apart.</p>
<p>Due to netarsudil’s vasodilating properties, other eye drops should be administered before netarsudil. Eye ointments should be administered last.</p>
- Route Of Administration
- OPHTHALMIC
- Indication Info
- <p><strong>1. INDICATIONS AND USAGE</strong><br>
RHOPRESSA (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension <em>[see section 12 Clinical Studies</em> – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em><em>]</em>.</p>
- Contraindications
- <p><strong>4. CONTRAINDICATIONS</strong><br>
Hypersensitivity to the active substance or to any of the excipients.</p>
- Atc Code
- S01EX05
- Atc Item Name
- netarsudil
- Pharma Manufacturer Name
- SANTEN PHARMACEUTICAL ASIA PTE. LTD.
